Skip to main content
  • Survival Advantage With Extended DAPT After MI? Updated meta-analysis enters the fray over antiplatelet duration

    Prolonged dual antiplatelet therapy (DAPT) actually conferred a survival advantage for prior MI patients, found an updated meta-analysis done as one argument in a set of viewpoints dueling over the 2016 guidelines.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details